Literature DB >> 15211988

Alpha-1 adrenoceptor hyperresponsiveness in three neuropathic pain states: complex regional pain syndrome 1, diabetic peripheral neuropathic pain and central pain states following spinal cord injury.

Robert W Teasell1, J Malcolm O Arnold.   

Abstract

The pathophysiology of the pain associated with complex regional pain syndrome, spinal cord injury and diabetic peripheral neuropathy is not known. The pain of complex regional pain syndrome has often been attributed to abnormal sympathetic nervous system activity based on the presence of vasomotor instability and a frequently reported positive response, albeit a temporary response, to sympathetic blockade. In contrast, the pain below the level of spinal cord injury and diabetic peripheral neuropathy are generally seen as deafferentation phenomena. Each of these pain states has been associated with abnormal sympathetic nervous system function and increased peripheral alpha-1 adrenoceptor activity. This increased responsiveness may be a consequence of alpha-1 adrenoceptor postsynaptic hypersensitivity, or alpha-2 adrenoceptor presynaptic dysfunction with diminished noradrenaline reuptake, increased concentrations of noradrenaline in the synaptic cleft and increased stimulation of otherwise normal alpha-1 adrenoceptors. Plausible mechanisms based on animal research by which alpha-1 adrenoceptor hyperresponsiveness can lead to chronic neuropathic-like pain have been reported. This raises the intriguing possibility that sympathetic nervous system dysfunction may be an important factor in the generation of pain in many neuropathic pain states. Although results to date have been mixed, there may be a greater role for new drugs which target peripheral alpha-2 adrenoceptors (agonists) or alpha-1 adrenoceptors (antagonists).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15211988     DOI: 10.1155/2004/150503

Source DB:  PubMed          Journal:  Pain Res Manag        ISSN: 1203-6765            Impact factor:   3.037


  8 in total

Review 1.  In search of analgesia: emerging roles of GPCRs in pain.

Authors:  Laura S Stone; Derek C Molliver
Journal:  Mol Interv       Date:  2009-10

Review 2.  A hypothesis for the cause of complex regional pain syndrome-type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology.

Authors:  Terence J Coderre; Gary J Bennett
Journal:  Pain Med       Date:  2010-08       Impact factor: 3.750

3.  Complex regional pain syndrome: what's in a name?

Authors:  Terence J Coderre
Journal:  J Pain       Date:  2010-07-15       Impact factor: 5.820

4.  Marked sympathetic component in the perivascular innervation of the dorsal paratendinous tissue of the patellar tendon in arthroscopically treated tendinosis patients.

Authors:  Patrik Danielson; Gustav Andersson; Håkan Alfredson; Sture Forsgren
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-04-17       Impact factor: 4.342

5.  Nerve-related characteristics of ventral paratendinous tissue in chronic Achilles tendinosis.

Authors:  Gustav Andersson; Patrik Danielson; Håkan Alfredson; Sture Forsgren
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2007-06-29       Impact factor: 4.342

6.  Hypersensitivity of vascular alpha-adrenoceptor responsiveness: a possible inducer of pain in neuropathic states.

Authors:  Robert W Teasell; Qingping Feng
Journal:  Neural Regen Res       Date:  2015-01       Impact factor: 5.135

7.  Norepinephrine-induced nociception and vasoconstrictor hypersensitivity in rats with chronic post-ischemia pain.

Authors:  Dimitris N Xanthos; Gary J Bennett; Terence J Coderre
Journal:  Pain       Date:  2008-01-14       Impact factor: 7.926

8.  Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.

Authors:  Juan M Politei; Didier Bouhassira; Dominique P Germain; Cyril Goizet; Antonio Guerrero-Sola; Max J Hilz; Elspeth J Hutton; Amel Karaa; Rocco Liguori; Nurcan Üçeyler; Lonnie K Zeltzer; Alessandro Burlina
Journal:  CNS Neurosci Ther       Date:  2016-03-28       Impact factor: 5.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.